[HTML][HTML] DNA methylation dynamics in blood after hematopoietic cell transplant

RM Rodriguez, B Suarez-Alvarez, R Salvanés… - PLoS …, 2013 - journals.plos.org
RM Rodriguez, B Suarez-Alvarez, R Salvanés, M Muro, P Martínez-Camblor, E Colado
PLoS One, 2013journals.plos.org
Epigenetic deregulation is considered a common hallmark of cancer. Nevertheless, recent
publications have demonstrated its association with a large array of human diseases. Here,
we explore the DNA methylation dynamics in blood samples during hematopoietic cell
transplant and how they are affected by pathophysiological events during transplant
evolution. We analyzed global DNA methylation in a cohort of 47 patients with allogenic
transplant up to 12 months post-transplant. Recipients stably maintained the donor's global …
Epigenetic deregulation is considered a common hallmark of cancer. Nevertheless, recent publications have demonstrated its association with a large array of human diseases. Here, we explore the DNA methylation dynamics in blood samples during hematopoietic cell transplant and how they are affected by pathophysiological events during transplant evolution. We analyzed global DNA methylation in a cohort of 47 patients with allogenic transplant up to 12 months post-transplant. Recipients stably maintained the donor’s global methylation levels after transplant. Nonetheless, global methylation is affected by chimerism status. Methylation analysis of promoters revealed that methylation in more than 200 genes is altered 1 month post-transplant when compared with non-pathological methylation levels in the donor. This number decreased by 6 months post-transplant. Finally, we analyzed methylation in IFN-γ, FASL, IL-10, and PRF1 and found association with the severity of the acute graft-versus-host disease. Our results provide strong evidence that methylation changes in blood are linked to underlying physiological events and demonstrate that DNA methylation analysis is a viable strategy for the study of transplantation and for development of biomarkers.
PLOS